| AM-Pharma (Bilthoven, The Netherlands) | hLF-1-11 (small peptide derived from human lactoferrin) | Phase 2 | Allogeneic bone marrow stem cell transplantation–associated infections |
| BioLineRx (Jerusalem) | BL2060 (a synthetic compound comprising fatty acid and lysine copolymers) | Lead optimization | Anti-infective |
| Ceragenix (Denver) | CSA-13 (cationic steroid (ceragenin) that mimics host-defense peptides) | Preclinical | Anti-infective |
| Helix Biomedix (Bothell, Washington, USA) | HB-50 (synthetic natural peptide mimetic of cecropin) | Preclinical | Anti-infective |
| HB-107 (19-amino-acid fragment of cecropin B) | Preclinical | Wound healing |
| Inimex (Vancouver, BC, Canada) | IMX942 (5-amino-acid peptide) | Lead optimization | Immunomodulation; treatment of fevers and neutropenia in chemotherapy patients |
| Lytix Biopharma (Tromso, Norway) | Not available | Discovery | Anti-infective, antitumor |
| Migenix (Vancouver, BC, Canada) | Omiganan pentahydrocholoride/ CP-226/MX-226/CLS001 (12-mer analog of bactolysin) | Phase 3b/phase 2 | Prevention of catheter-related infections; dermatology-related infections |
| Novacta Biosystems Ltd. (Hatfield, England) | Mersacidin (bacteriocin) | Preclinical | Gram-positive infections |
| Novobiotics (Cambridge, Massachusetts, USA) | Not available | Discovery | Nail fungus; methicillin-resistant S. aureus |
| Novozymes A/S (Bagsvaerd, Denmark) | Plectasin (fungal defensin) | Preclinical | Systemic anti–Gram positive, especially pneumococcal and streptococcal infections |
| Pacgen (Vancouver, BC, Canada) | PAC113 (based on the active segment of histatin 5 protein found in human saliva) | Investigational New Drug (IND) approval | Oral candidiasis |
| PepTx (St. Paul, MN, USA) | PTX002 (33-mer peptide) PTX005 (12-mer peptide), PTX006 (N-acylated analog of PTX005) and PTX007 (a nonpeptidic structural analog of PTX005) | Discovery | Broad-spectrum antimicrobial antiendotoxin |
| Polymedix (Philadelphia) | Peptidomimetics (derived from the arylamide, calixarene, hydrazide and salicylamide series) | Discovery/preclinical | Anti-infectives; antimicrobial polymers and coating materials |
| Zengen (Woodland Hills, CA, USA) | CZEN-002 (synthetic 8-mer derived from  -melanocyte–stimulating hormone) | Phase 2b | Vulvovaginal candidiasis |
 |
|
|
This is a listing of known antimicrobials in development and/or clinical trials in private companies. Most of this information is based on a review by Zhang & Falla22, as gleaned by them and updated by us primarily from company press releases, public presentations and the AdisInsight 'R&D Insight' database (http://www.adisinsight.com). We do not include in this table several peptides that went through clinical trials but were not approved.
|
